期刊
DRUGS OF TODAY
卷 55, 期 10, 页码 641-652出版社
PROUS SCIENCE, SAU-THOMSON REUTERS
DOI: 10.1358/dot.2019.55.10.3030646
关键词
Crizotinib; Ceritinib; Entrectinib; Lorlatinib; Repotrectinib; DS-6051b; Cabozantinib; ROS1 gene fusions; Tyrosine kinase inhibitors; Non-small cell lung cancer (NSCLC); ROS1(+) NSCLC; Cancer therapy
ROS1 gene fusions account for approximately 1-2% of all cases of non-small cell lung cancer (NSCLC). Similarly to anaplastic lymphoma kinase (ALK)-positive NSCLC, patients with ROW NSCLC tend to have minimal smoking and be of the female sex. In most cases, adenocarcinoma is the dominant histology. The ROS1 gene has homology to ALK and this structural similarity formed the basis for utilizing ALK inhibitors for ROS1(+) NSCLC. On the basis of impressive progression-free survival of 19.2 months from the PROFILE 1001 trial, crizotinib obtained Food and Drug Administration (FDA) approval as first-line therapy for treatment of ROS1(+) NSCLC. Since then, there has been a growing appreciation of the incidence of brain metastases in ROSE NSCLC and rates of central nervous system progression on crizotinib. Additionally, appreciation of novel resistance mechanisms to crizotinib has led to the development of newer tyrosine kinase inhibitors (TKIs). In this review, we highlight known and emerging TKIs for the management of ROS1(+ )NSCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据